GLP1R and obstructive sleep apnea syndrome: Current perspectives depict the weight loss induced by GLP-1 receptor agonists as the central mechanism underlying their beneficial role in OSA patients, also considering previous studies supporting the therapeutic effect of weight loss itself in obese OSA patients through reduction in AHI and systemic inflammation, but other potential mechanisms are under investigation (e.g., direct regulation of hypothalamic functions, reduction in sympathetic activity, independent reduction in systemic inflammation) [37,39].